Enzolytics Inc (ENZC)

[falon]

ENZC

The Company's targeted approach is to produce fully human monoclonal antibodies against the identified conserved epitopes on the Coronavirus. Using computer analysis (Artificial Intelligence [AI]), the Company has identified 19 conserved sequences identified on the Coronavirus on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed. Significantly, these conserved sequences have been identified in the UK, Brazil and South African variants.

This discovery is significant in Enzolytics' continued commitment to producing therapeutics for the treatment of COVID-19. Specifically, Enzolytics is creating human heterohybridoma cell lines using convalescent human patients' peripheral "immune" human B cells to create fully human monoclonal antibodies directed individually against the identified conserved sites on the virus and against both S1 protein and S2 (transmembrane) protein on the Coronavirus. These monoclonal antibodies will expectedly have universal effect (on all known variants) and will be durable in that as the virus mutates, the targeted site will still exist in the virus subjecting it to neutralization. Such therapeutics would have universal (world-wide application), be durable (have long term successful benefit) and thereby prevent failure of successful vaccines and/or provide effective treatment, which are both points of failures that have occurred as a result of "mutational virus escape".

The Company's pending patents claim the identified target sites and include patent claims to the CDR sequences of the produced antibodies. Such patent claim structure will expectedly provide the Company the exclusive rights to therapeutics based on these findings for a 20 years period from the date of filing. International patent coverage is also being sought.
https://money.yahoo.com/coronavirus-targeted-epitopes-claimed-enzolytics-140000567.html


REGN

We have one of the most sophisticated and largest screening efforts for COVID antibodies, and we believe we have identified one-in-a-million antibody that works very differently to all prior antibodies by binding outside of the immuno-dominant highly variable RBD and NTD domains. These domains have been the primary site of antibody binding and correspondingly of variant mutations.

We have caused the initial vaccines in previous COVID antibody therapies to lose their activities. We hope that by binding outside of these domains to a unique targeted epitope that is highly conserved, with over 99.9% conservations since the beginning of the pandemic, it will lower the risk of losing activity against future variants. Importantly, this antibody, known as REGEN14287 demonstrates high neutralization potency against all known SARS-CoV-2 variants and lineages to date. Activities enabling clinical manufacturing have commenced, and we expect to enter clinical development later this year.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170955564